Expand Energy Corporation enters the final week of August with a meaningful shift in the data: the analyst pressure that defined the prior note has cracked, short sellers are unwinding at pace, and options defensiveness — the dominant theme two weeks running — has reversed sharply.
The single most important development is Goldman Sachs analyst Neil Mehta raising his price target on EXE to $113 from $99 this morning, while maintaining his Buy rating. That breaks the run of cuts that had dominated since mid-August — Johnson Rice downgrading, Barclays trimming, Benchmark slashing from $124 to $109, and Morgan Stanley nudging lower last week. The Goldman move doesn't change the consensus direction entirely: the mean target remains near $125 against a current price of $94.66, leaving roughly 33% implied upside on paper. But Mehta's $14 lift is the first material upward revision in weeks, and it lands from a bellwether firm. The bull case centers on a 48% rise in net asset value per share and 15% year-over-year production growth. The bear case — an 11% decline in well productivity and a projected dip in volumes through early 2026 — hasn't gone away, but the Goldman action signals at least one major house thinks the recent target-cutting cycle overshot.
The positioning story has flipped direction just as clearly. Short interest has fallen to 3.0% of the free float, down 15.5% on the week and 22.6% over the past month — a sustained, broad-based cover rather than a one-day event. In early August, shorts held closer to 4.5% of the float; that position has been methodically unwound through every week since. The lending market reflects the same looseness: cost to borrow runs at just 0.41%, barely moved despite the cover activity, and availability is extraordinarily ample at over 2,100% — meaning more than twenty shares are available to borrow for every one currently lent out. There is no squeeze dynamic at work here; shorts are leaving of their own accord, not being forced out.
Options tell a directly contrasting story to the defensiveness flagged two weeks ago. The put/call ratio has dropped to 1.09, more than two standard deviations below its 20-day average of 1.29 — its most bullish reading in that window. A month ago the PCR was running above 1.40; as recently as last week it sat above 1.38. The rotation from elevated put demand to call-skewed positioning is sharp and consistent across several sessions. That shift aligns with the short cover: two separate expressions of reduced bearish conviction arriving in the same week.
Insider activity provides a quieter but supportive backdrop. The Chairman and CFO both made open-market purchases in early June at prices between $89 and $93 — below the current $94.66. Net insider buying over the trailing 90 days amounts to 6,000 shares, worth roughly $561,000. The significance scores on these trades are modest, but the direction is unambiguous, and the Chairman's repeat buying across two separate dates adds weight to the signal.
EXE's closest peers had a better week than EXE itself, which slipped 0.8%. RRC gained 2.8%, AR rose 2.5%, and CRK added 3.7%. The sole notable laggard was BKV, down nearly 10% on the week. EXE's relative underperformance is consistent with the momentum drag flagged in prior notes — the ORTEX short score has been easing steadily from 40.5 on August 13 to 33.5 today, reflecting the improving short setup even as price lags the group. The next scheduled earnings release is October 27, and the last two prints both produced positive one-day and five-day moves — the most recent delivering a 4.4% gain the day after — making that date the next real test of whether the fundamental narrative is turning alongside the positioning.
See the live data behind this article on ORTEX.
Open EXE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
